-+ 0.00%
-+ 0.00%
-+ 0.00%

Sionna Therapeutics completes enrollment in Phase 2a PreciSION CF trial of SION-719

PUBT·04/27/2026 11:02:10
Listen to the news
Sionna Therapeutics completes enrollment in Phase 2a PreciSION CF trial of SION-719
  • Sionna Therapeutics completed enrollment in PreciSION CF, a Phase 2a proof-of-concept trial testing SION-719 added to Trikafta in adults with cystic fibrosis.
  • Results have not been presented; topline data are expected in summer 2026.
  • Study aims to show whether SION-719 can improve CFTR function when used on top of current standard of care, while remaining safe and tolerable.
  • Program positions SION-719 as a first-in-class approach targeting the underlying defect linked to the most common CF-causing mutation, supporting Sionna’s strategy to extend benefits beyond existing modulators.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270700PRIMZONEFULLFEED9696829) on April 27, 2026, and is solely responsible for the information contained therein.